Clinical Course of Neurologic Adverse Events Associated With Immune Checkpoint Inhibitors
Simone Rossi, Antonio Farina, Antonio Malvaso, Alessandro Dinoto, Laura Fionda, Sara Cornacchini, Irene Florean, Luigi Zuliani, Matteo Garibaldi, Antonio Lauletta, Flavia Baccari, Corrado Zenesini, Rita Rinaldi, Sara Mariotto, Valentina Damato, Luca Diamanti, Matteo Gastaldi, Alberto Vogrig, Enrico Marchioni, Maria Guarino
Abstract
BACKGROUND AND OBJECTIVES: The clinical course and the risk of chronicity of neurologic immune-related adverse events (n-irAEs) associated with immune checkpoint inhibitors (ICIs) are not well documented. This study aimed to characterize the clinical course of n-irAEs and assess the prevalence of chronic events. METHODS: (if patients had neurologic sequelae without ongoing inflammation). Comparisons between groups and time-to-death analyses were performed. RESULTS: < 0.01), primarily due to cancer progression. DISCUSSION: More than half of the patients with n-irAEs who survived the acute phase developed a chronic condition. Patients with chronic n-irAEs were at higher risk of death, mainly due to cancer progression. Future studies are needed to further characterize chronic n-irAEs and identify optimal long-term management strategies.